Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrate...
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
About this item
Full title
Author / Creator
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
ObjectivesTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.MethodsData were pooled for all tofacitinib-treated patients (data cut-off:...
Alternative Titles
Full title
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5530353
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5530353
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2016-210457
